Ketolar

Ketamine, the active ingredient in Ketolar, is a NMDA receptor antagonist presented as a sterile injectable solution for intramuscular and intravenous use. It is employed in anesthesia, analgesia and sedation, and is also investigated off‑label for treatment‑resistant depression in appropriate clinical settings.

GNH USA supplies Ketolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketolar acts on the central nervous system by blocking NMDA receptors, providing anesthetic and analgesic effects. - Anesthesia: induces a reversible loss of consciousness and analgesia for surgical procedures. - Analgesia: provides profound pain relief during and after surgery or in acute pain management. - Sedation: facilitates deep sedation for diagnostic or therapeutic interventions. - Treatment‑resistant depression (off‑label): may produce rapid antidepressant effects under specialist supervision.

Ketolar may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hypertension: transient increase in blood pressure during administration. - Tachycardia: elevated heart rate observed in some patients. - Nausea: mild to moderate feeling of queasiness. - Vomiting: occasional emesis following dosing. - Dizziness: sensation of light‑headedness or unsteadiness. - Visual disturbances: blurred vision or altered perception.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort requiring support. - Emergence reactions: vivid dreams, agitation, or hallucinations during recovery. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals. - Elevated intracranial pressure: worsening of pre‑existing conditions. - Hepatotoxicity: rare liver enzyme elevations. - Allergic reactions: rash, itching, or anaphylaxis in extreme cases.

Ketolar should be administered by qualified healthcare professionals with appropriate monitoring. - Cardiovascular assessment: evaluate blood pressure and heart rate before use. - Respiratory monitoring: ensure adequate ventilation and oxygenation during and after administration. - Psychiatric history: consider risk of emergence reactions in patients with psychosis. - Substance abuse: use caution in individuals with a history of ketamine misuse. - Drug interactions: review concomitant medications for potential additive CNS effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ketolar can interact with other agents that affect the central nervous system or cardiovascular function.

Major Interactions (Avoid): - Central depressants (e.g., benzodiazepines, opioids): may cause profound respiratory depression. - Sympathomimetic agents (e.g., epinephrine): can exacerbate hypertension and tachycardia.

Moderate Interactions (Monitor Closely): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Anticholinergic drugs: may increase intra‑ocular pressure. - CYP450 substrates (e.g., CYP2B6, CYP3A4): ketamine metabolism may be altered, affecting drug levels.